Kymera Therapeutics, Inc. KYMR
Set alert
At close · Nov 2
After hours · Nov 2, 4:33 PM ET
- YTD
- +63.87%
- 1 year
- +106.19%
- Open
- 127.00
- Prev close
- 126.63
- Mkt cap
- 10.89B
- Vol
- 1.29M
- Avg vol
- 774.47K
- EPS
- -3.63
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 124.30
- High
- 129.34
- Forward P/E
- -25.30
- Beta
- 2.03
- Short ratio
- 10.32
- Inst. own
- 116.24%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 25, 2027
- 50-d avg
- 114.92
- 200-d avg
- 96.42
- 1y target
- 144.39
1D chart
Events in this range
- Nov 2, 2026Rating: Barclays · Overweight → Overweight
Signals (18)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | 11:13 AM | 11 hours ago |
| RSI: Oversold | 10:56 AM | 11 hours ago |
| SMA: Bearish | 10:54 AM | 11 hours ago |
| SMA: Bullish | 10:53 AM | 11 hours ago |
| SMA: Bearish | 10:52 AM | 11 hours ago |
| MACD: Sell Signal | 10:47 AM | 11 hours ago |
| SMA: Bullish | 10:36 AM | 11 hours ago |
| SMA: Bullish | 10:34 AM | 11 hours ago |
| SMA: Bearish | 10:32 AM | 11 hours ago |
| SMA: Bearish | 10:29 AM | 11 hours ago |
| SMA: Bullish | 10:25 AM | 11 hours ago |
| MACD: Buy Signal | 10:23 AM | 12 hours ago |
| MACD: Sell Signal | 10:16 AM | 12 hours ago |
| MACD: Buy Signal | 10:10 AM | 12 hours ago |
| MACD: Sell Signal | 10:08 AM | 12 hours ago |
| MACD: Buy Signal | 10:07 AM | 12 hours ago |
| MACD: Sell Signal | 10:04 AM | 12 hours ago |
| SMA: Bearish | 10:00 AM | 12 hours ago |
Key statistics
- Market cap
- 10.89B
- Enterprise value
- 9.92B
- Trailing P/E
- 0.00
- Forward P/E
- -25.30
- PEG ratio
- 0.00
- Price / sales
- 106.48
- Price / book
- 6.74
- EPS (TTM)
- -3.64
- Beta
- 2.03
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 102.23M
- Revenue growth
- 0.00%
- Free cash flow
- -164.68M
- Total cash
- 971.21M
- Total debt
- 76.60M
- Return on equity
- -27.29%
- Shares outstanding
- 85.37M
- Short % of float
- 13.73%
- 50-day average
- 114.92
- 200-day average
- 96.42
Analyst view
Consensus: strong buy
- Target (low)
- 112.00
- Target (mean)
- 144.39
- Target (high)
- 180.00
- Strong buy5
- Buy17
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -1.26.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -1.30 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | -1.26 | -1.32 | -0.06 | -4.76% |
| Aug 5, 2026 | Jun 30, 2026 | -0.7126 | -0.62 | +0.09 | +12.99% |
| Apr 30, 2026 | Mar 31, 2026 | -0.89 | -0.71 | +0.18 | +20.22% |
| Feb 26, 2026 | Dec 31, 2025 | -0.78366 | -0.97 | -0.19 | -23.78% |
| Nov 4, 2025 | Sep 30, 2025 | -0.71 | -0.90 | -0.19 | -26.76% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Barclays | main | Overweight | Overweight |
| Oct 30, 2026 | Truist Securities | reit | Buy | Buy |
| Oct 30, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 29, 2026 | BTIG | main | Buy | Buy |
| Oct 27, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Oct 9, 2026 | Raymond James | init | — | Outperform |
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kymeratx.com
News
- Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170
- Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150
- RBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116
- BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139
- Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript
- Kymera Therapeutics Q3 Earnings Call Highlights
- Kymera Therapeutics Q3 EPS $(1.32) Misses $(1.27) Estimate
- Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
- Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
- Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146
Your note
Sign in to keep a note on KYMR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS BRIAN R | Officer | Sale | Sep 3, 2026 | 50,254 |
| BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 10, 2025 | 0 |
| BVF PARTNERS L P | Affiliated Person | Purchase | Jun 29, 2025 | 0 |
| BVF PARTNERS L.P. | Affiliated Person | Sale | Jun 25, 2026 | 0 |
| CHADWICK JEREMY G | Chief Operating Officer | Sale | May 26, 2026 | 44,018 |
| CHINIARA ELLEN V | Officer | Sale | Mar 2, 2025 | 80,085 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.47% | 12,349,256 | 1.57B | Jun 29, 2026 |
| Baker Bros. Advisors, LP | 10.14% | 8,657,242 | 1.10B | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 8.76% | 7,474,747 | 953.11M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 8.33% | 7,112,980 | 906.98M | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 7.33% | 6,257,261 | 797.86M | Jun 29, 2026 |
| Blackrock Inc. | 6.49% | 5,538,210 | 706.18M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price New Horizons Fund, Inc. | 2.64% | 2,257,207 | 287.82M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.63% | 2,241,647 | 285.83M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.45% | 2,089,249 | 266.40M | Jun 29, 2026 |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 2.40% | 2,046,104 | 260.90M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.10% | 1,796,469 | 229.07M | Jul 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.90% | 1,621,725 | 206.79M | Sep 29, 2026 |